Drawing for ACCORD

USPTO serial 98676711

ACCORD

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
MCMORROW, RONALD G
Law office
TMO LAW OFFICE 118

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with ACCORD?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michele K. Robichaux

Michele K. Robichaux ODIN LAW AND MEDIA4208 Six Forks Rd., STE 1000RALEIGH, NC 27609United States

Goods and services

ClassDescriptionStatusFirst use
035Pharmaceutical services, namely, processing orders for pharmaceutical products and pharmaceutical preparations from retail and central fill pharmacies and healthcare facilities; wholesale store services featuring prescription pharmaceutical products and pharmaceutical preparationsACTIVEJan 1, 2015
042Pharmaceutical drug development services; Pharmaceutical products development; Development of pharmaceutical preparations and medicines; Pharmaceutical research and development; Pharmaceutical research services.ACTIVEJan 1, 2015

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Sep 17, 2025MAB2ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Sep 17, 2025ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
May 23, 2025GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
May 23, 2025GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
May 23, 2025CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
May 7, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 7, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 7, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 24, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 24, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 24, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Feb 12, 2025GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 12, 2025GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 12, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 11, 2025DOCKASSIGNED TO EXAMINER—
Feb 11, 2025DOCKASSIGNED TO EXAMINER—
Feb 10, 2025MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Feb 10, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 5, 2024TAEATEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED—
Aug 5, 2024PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Jul 31, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance